Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended June 28, 2008 (First Quarter of Fiscal Year 2009)
Business Overview: Haemonetics designs, manufactures, and markets automated blood processing systems, including devices and single-use disposables for blood donors and surgical patients, as well as software solutions for blood and plasma collection centers.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 FY2009 (Ended June 28, 2008) |
Q1 FY2008 (Ended June 30, 2007) |
|---|---|---|
| Net Revenues | $144,116 | $121,936 |
| Gross Profit | $73,037 | $61,494 |
| Gross Margin | 50.7% | 50.4% |
| Operating Income | $19,334 | $15,779 |
| Operating Margin | 13.4% | 12.9% |
| Net Income | $14,341 | $12,677 |
| Diluted EPS | $0.54 | $0.46 |
| Cash and Cash Equivalents | $120,287 | $216,056 (End of Period) |
| Working Capital | $256,530 | $261,757 (Prior Quarter) |
| Net Cash Provided by Operating Activities | $13,842 | $14,181 |
| Total Debt (Current + Long-term) | $14,910 | $12,363 (Prior Quarter) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 18.2% year-over-year. This was driven by a 13.2% organic increase in unit sales and a 5.0% favorable impact from foreign exchange rates.
- Product Performance:
- Donor Products: Disposables revenue grew 18.1%, led by a 30.4% increase in Plasma products and 8.0% in Blood Bank products.
- Patient Products: Disposables revenue grew 25.2%, with Surgical & Diagnostic products surging 34.0% due to the inclusion of the Haemoscope TEG business acquired in the prior fiscal year.
- Operating Expenses: Total operating expenses rose 17.5% to $53.7 million. Selling, General, and Administrative (SG&A) expenses increased 21.3%, largely due to integration costs from recent acquisitions (Haemoscope, Medicell, Infonalé) and foreign exchange impacts. Research and Development expenses decreased 6.9%.
- Acquisitions: The company acquired Medicell Ltd. (a UK distributor) for approximately $2.4 million in cash plus contingent consideration on April 4, 2008.
- Tax Rate: The effective tax rate decreased to 29.5% from 31.2%, primarily due to a $1.1 million reversal of previously accrued foreign income taxes in Japan following the expiration of the statute of limitations.
Guidance, Outlook, and Risks
- Outlook: Management expects the annual effective tax rate to be approximately 35.1% for the remainder of fiscal year 2009.
- Restructuring: On May 1, 2008, management announced a transformation plan for Technical Operations. The company expects to incur total exit-related costs of $7 million to $8 million over fiscal year 2009. $1.2 million of these costs were incurred in the current quarter.
- Capital Allocation: The Board authorized a $60.0 million share repurchase program in May 2008. As of June 28, 2008, the company had repurchased approximately 515,000 shares for $28.8 million, with $31.2 million remaining under the authorization.
- Foreign Exchange: Approximately 54% of sales are generated outside the U.S. The company uses forward contracts to hedge anticipated cash flows. A strengthening U.S. dollar adversely affects results, while a weakening dollar has a positive effect.
- Risks: Key risks include foreign currency fluctuations, regulatory requirements, market acceptance of new products, and the impact of industry consolidation in the plasma market.
Investor Verification Checklist
- Acquisition Integration: Verify the financial contribution and integration progress of the Haemoscope and Medicell acquisitions, which drove significant revenue growth but also increased SG&A expenses.
- Restructuring Costs: Monitor the execution of the Technical Operations transformation plan and the total cost impact ($7M-$8M) on future operating margins.
- Foreign Exchange Exposure: Assess the impact of the U.S. dollar strength on future quarters, given that 54% of revenue is international and hedging strategies are in place.
- Share Repurchases: Track the remaining $31.2 million authorization and the company's commitment to returning capital to shareholders.
- Tax Rate Volatility: Confirm the sustainability of the tax rate, noting the one-time $1.1 million benefit from the Japanese statute of limitations expiration.